T. Lange

M. Sorror, R. Storb, B. Sandmaier, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma

P. Hari, R. Storb, B. Sandmaier, 2018, Haematologica.

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib

G. Behre, D. Niederwieser, C. Wickenhauser, 2014, Bone Marrow Transplantation.

JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse

D. Niederwieser, M. Cross, C. Wickenhauser, 2013, Haematologica.

Myeloproliferative Neoplasien

C. Junghanss, F. Heidel, C. Wickenhauser, 2012, best practice onkologie.

Molecular diagnostics in chronic myeloid leukemia.

M. Deininger, T. Lange, 2010, Expert opinion on medical diagnostics.

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.

Jennifer L. Snead, B. Druker, M. Deininger, 2009, Blood.

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study

M. Scholz, D. Niederwieser, U. Platzbecker, 2022, Journal of Cancer Research and Clinical Oncology.

Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.

A. Hinke, H. Schmoll, A. Tannapfel, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

P. Szankasi, D. Marin, B. Druker, 2013, Blood.

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia

U. Dührsen, H. Serve, O. Ottmann, 2012, Leukemia.

patients on imatinib BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia

G. Superti-Furga, O. Hantschel, I. Kaupe, 2011 .

Philadelphia-positive acute lymphoblastic leukemia ( Ph imatinib-based therapy and give rise to relapse in patients with de novo Kinase domain mutations of BCR-ABL frequently precede

J. Oldenburg, A. Pavlova, A. Hochhaus, 2007 .

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

J. Cayuela, V. V. D. van der Velden, T. Lion, 2019, Leukemia.

Optimized Digital Droplet PCR for BCR-ABL.

D. Niederwieser, M. Cross, T. Lange, 2019, The Journal of molecular diagnostics : JMD.

Comparison of Real-Time quantitative PCR and digital droplet PCR for BCR-ABL1 Monitoring in Patients with Chronic Myeloid Leukemia.

Martin C. Müller, D. Niederwieser, F. Giles, 2020, The Journal of molecular diagnostics : JMD.

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

D. Colomer, T. Lion, G. Martinelli, 2015, Leukemia.

Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia.

M. Maris, R. Storb, B. Sandmaier, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic impact of the CD34+/CD38− cell burden in patients with acute myeloid leukemia receiving allogeneic stem cell transplantation

C. Bloomfield, K. Mrózek, G. Behre, 2017, American journal of hematology.

Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).

D. Niederwieser, G. Ehninger, W. Aulitzky, 2015, Annals of Oncology.

Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.

M. Maris, R. Storb, B. Sandmaier, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients

G. Behre, D. Niederwieser, M. Cross, 2018, Annals of Hematology.

Prognostic relevance of DNMT3A R882 mutations in AML patients undergoing non-myeloablative conditioning hematopoietic stem cell transplantation

G. Behre, D. Niederwieser, M. Cross, 2018, Bone Marrow Transplantation.

Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning

G. Behre, D. Niederwieser, M. Cross, 2017, Bone Marrow Transplantation.

D. Niederwieser, C. Junghanss, H. Al-Ali, 2009, Leukemia.

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors.

M. Maris, R. Storb, B. Sandmaier, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients

G. Behre, D. Niederwieser, S. Schwind, 2017, Oncotarget.

BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning

R. Brand, D. Niederwieser, U. Hegenbart, 2004, Leukemia.

Design and Methods

S. Iacobelli, R. Brand, A. Nagler, 2022 .

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib

Martin C. Müller, D. Niederwieser, K. Porkka, 2009, Haematologica.

BCR-ABL kinase domain mutations on second line dasatinib or nilotinib therapy in chronic myeloid leukemia patients after imatinib failure : a cooperative evaluation of different detection methods

Martin C. Müller, D. Niederwieser, K. Porkka, 2009 .

Reduced-Intensity Conditioning in Allogeneic StemCell Transplantation for Hematological Malignancies:A Historical Perspective

B. Sandmaier, M. Hallek, U. Holtick, 2011, Oncology Research and Treatment.

Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients

R. Engh, K. Porkka, I. Mikkola, 2012, Leukemia.

Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapy

D. Niederwieser, C. Wickenhauser, U. Siebolts, 2010, Journal of Clinical Pathology.

Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions

C. Junghanss, F. Heidel, H. Al-Ali, 2018, Leukemia.

JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib

D. Niederwieser, C. Wickenhauser, U. Siebolts, 2015, Annals of Hematology.

The impact of the age of HLA-identical siblings on mobilization and collection of PBSCs for allogeneic hematopoietic cell transplantation

D. Niederwieser, H. Al-Ali, R. Krahl, 2011, Bone Marrow Transplantation.

The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia

Martin C. Müller, D. Niederwieser, M. Cross, 2013, Haematologica.

onmyeloablative Unrelated Donor Hematopoietic Cell ransplantation to Treat Patients with Poor-Risk , elapsed , or Refractory Multiple Myeloma

M. Sorror, M. Maris, R. Storb, 2007 .

e8a2 BCR–ABL: more frequent than other atypical BCR–ABL variants?

P. Paschka, G. Martinelli, A. Hochhaus, 2005, Leukemia.

Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.

M. Sorror, M. Maris, R. Storb, 2006, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Prognostic value of T-1 cell numbers prior to allogeneic stem cell transplantation in patients with severe graft-versus-host disease

D. Niederwieser, U. Banning, D. Körholz, 2005, Bone Marrow Transplantation.

Parotitis associated with a parainfluenza virus type 3 infection during aplasia after unrelated allogeneic stem cell transplantation

D. Niederwieser, T. Lange, Georg-Nikolaus Franke, 2006, Leukemia & lymphoma.

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation

P. Hari, M. Maris, R. Storb, 2014, Haematologica.

Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.

M. Sorror, M. Maris, R. Storb, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A Novel Method to Quantify and Characterize Leukemia-Reactive Natural Killer Cells in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation following Conventional or Reduced-Dose Conditioning

E. Thiel, A. Stroux, A. Muessig, 2007, International journal of hematology.

Allogeneic hematopoietic cell transplantation (HCT) following reduced-intensity conditioning in patients with acute leukemias.

D. Niederwieser, U. Hegenbart, H. Al-Ali, 2005, Critical reviews in oncology/hematology.

Low-dose total body irradiation-based regimens as a preparative regimen for allogeneic haematopoietic cell transplantation in acute myelogenous leukaemia

D. Niederwieser, M. Cross, H. Al-Ali, 2009, Current opinion in oncology.

Determination of Saliva Trough Levels for Monitoring Voriconazole Therapy in Immunocompromised Children and Adults

D. Niederwieser, R. Preiss, U. Bierbach, 2010, Therapeutic drug monitoring.

Voriconazole Pharmacokinetics and Safety in Immunocompromised Children Compared to Adult Patients

D. Niederwieser, R. Preiss, U. Bierbach, 2010, Antimicrobial Agents and Chemotherapy.

Bcr–Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia

D. Niederwieser, M. Cross, H. Al-Ali, 2012, Leukemia & lymphoma.

Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

P. Hari, M. Sorror, R. Storb, 2009, Blood.

with imatinib response in chronic-phase chronic myeloid leukemia patients treated cells to predict major cytogenetic + A gene expression signature of CD34

Jennifer L. Snead, Y. Turpaz, C. Harrington, 2011 .

A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib.

Beth Wilmot, Shannon K McWeeney, Jennifer L. Snead, 2010, Blood.

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

B. Druker, M. Heinrich, D. Niederwieser, 2004, The hematology journal : the official journal of the European Haematology Association.

Residual disease in chronic myeloid leukemia after induction of molecular remission.

M. Deininger, D. Niederwieser, T. Lange, 2003, The New England journal of medicine.

High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML.

D. Niederwieser, H. Al-Ali, R. Krahl, 2003, Blood.

BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

R. Larson, R. Baron, M. Baccarani, 2014, Cancer cell.

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissio

R. Storb, B. Sandmaier, D. Maloney, 2003, Blood.

Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR

D. Niederwieser, M. Cross, H. Al-Ali, 2008, Leukemia.

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.

G. Superti-Furga, O. Hantschel, I. Kaupe, 2010, Blood.

Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST)

P. Hohenberger, K. Specht, C. Peschel, 2019, International journal of cancer.

Detection of Mutant Free Circulating Tumor DNA in the Plasma of Patients with Gastrointestinal Stromal Tumor Harboring Activating Mutations of CKIT or PDGFRA

D. Niederwieser, K. Specht, C. Peschel, 2013, Clinical Cancer Research.

Comparable outcome after single-antigen-mismatched versus matched unrelated donor haematopoietic cell transplantation

G. Behre, D. Niederwieser, M. Cross, 2015, Journal of Cancer Research and Clinical Oncology.

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR

H Emons, V Kairisto, S Trapmann, 2014, Leukemia.

Wireless capsule endoscopy for diagnosis of acute intestinal graft-versus-host disease.

D. Niederwieser, A. Tannapfel, K. Caca, 2007, Gastrointestinal endoscopy.

UVA (UVA-1) therapy for the treatment of acute GVHD of the skin

D. Niederwieser, J. Simon, H. Al-Ali, 2010, Bone Marrow Transplantation.

Favorable outcome in children and adolescents with a high proportion of advanced phase disease using single/multiple autologous or matched/mismatched allogeneic stem cell transplantations

G. Behre, B. Gruhn, D. Körholz, 2016, Annals of Hematology.

Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors

M. Maris, R. Storb, B. Sandmaier, 2006 .

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

T. Brümmendorf, F. Finkernagel, M. Huber, 2017, Leukemia.

Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation

E. Thiel, D. Niederwieser, R. Heilbronn, 2007, Bone Marrow Transplantation.

Long-term Outcome of Patients with Multiple Myeloma after Autologous Hematopoietic Cell Transplantation and Nonmyeloablative Allografting Running title: Auto-Allotransplant in Multiple Myeloma

P. Hari, M. Sorror, R. Storb, 2008 .

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

T. Brümmendorf, F. Finkernagel, M. Huber, 2018, Leukemia.

Frequency of CTLA-4 Receptor Ligand (CD86, B7.2) -Positive Plasmacytoid Dendritic Cells Predicts Risk of Disease Recurrence after Tyrosine-Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Results from a Prospective Substudy of the Euroski Trial

Martin C. Müller, T. Brümmendorf, F. Mahon, 2015 .

Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma.

M. Sorror, R. Storb, B. Sandmaier, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia

G. Behre, D. Niederwieser, M. Cross, 2019, HemaSphere.

Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia

S. Iacobelli, G. Behre, D. Niederwieser, 2014, Leukemia & lymphoma.

Non‐myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B‐cell lymphoma: a multicentre experience

M. Sorror, R. Storb, B. Sandmaier, 2008, British journal of haematology.

Monitoring of WT1 expression in PB and CD34+ donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning

M. Scholz, D. Niederwieser, J. Edelmann, 2011, Leukemia.

Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia

H. Rammensee, S. Stevanović, D. Niederwieser, 2008, Leukemia.

ORIGINAL ARTICLE Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia

H. Rammensee, S. Stevanović, Eberhard Karls, 2008 .

Complete Resolution of a Pulmonary Aspergillosis on Third-Line Posaconazole and Immunosupression Taper After Allogeneic Hematopoietic Cell Transplantation

D. Niederwieser, T. Lange, G. Genzel, 2009 .

A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A M

M. Maris, R. Storb, B. Sandmaier, 2009 .

Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV)

D. Niederwieser, R. Krahl, S. Schwind, 2017, Journal of Cancer Research and Clinical Oncology.

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

J. Beck, D. Niederwieser, T. Lange, 2013, British journal of haematology.

Prospective phase II study of preemptive chimerism-driven reduction of immunosuppression after non-myeloablative conditioning—Eudract #: 2007-002420-15

D. Niederwieser, J. Edelmann, M. Cross, 2022, Bone Marrow Transplantation.

Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.

M. Maris, R. Storb, B. Sandmaier, 2004 .

Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.

J. Radich, R. Storb, B. Sandmaier, 2004 .

Clinical impact of clonal hematopoiesis in acute myeloid leukemia patients receiving allogeneic transplantation

G. Behre, D. Niederwieser, M. Cross, 2018, Bone Marrow Transplantation.

Complete Clinical, Histopathologic and Molecular Remission of Primary Myelofibrosis with Long-Term Treatment with the JAK1/2 Inhibitor Ruxolitinib

D. Niederwieser, U. Siebolts, H. Al-Ali, 2014 .

International Standardization of Minimal Residual Disease Assessment for in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) Expressing m-BCR-ABL Transcripts: Updated Results of Quality Control Procedures by the EWALL and ESG-MRD-ALL Consortia

E. Yeoh, J. Cayuela, B. Schäfer, 2011 .

No advantage of Imatinib in combination with hydroxyurea over Imatinib monotherapy: a study of the East German Study Group (OSHO) and the German CML study group

D. Niederwieser, C. Junghanss, M. Cross, 2020, Leukemia & lymphoma.

Value of liver elastography and abdominal ultrasound for detection of complications of allogeneic hemopoietic SCT

D. Niederwieser, V. Keim, T. Karlas, 2014, Bone Marrow Transplantation.

Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.

A. Hinke, A. Tannapfel, S. Al-Batran, 2018, European journal of cancer.

Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib

T. Brümmendorf, F. Giles, S. Koschmieder, 2015, Leukemia.

Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma

D. Niederwieser, S. Schwind, T. Lange, 2015, Journal of Cancer Research and Clinical Oncology.

Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study

M. Scholz, D. Niederwieser, U. Platzbecker, 2022, Journal of Cancer Research and Clinical Oncology.

Delayed processing of bone marrow samples reveals a prognostic pattern of NME mRNA expression in cytogenetically normal acute myeloid leukemia

T. Haferlach, D. Niederwieser, T. Büchner, 2012, Leukemia & lymphoma.

High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia

H. Erickson, J. Tyner, M. Loriaux, 2009, Leukemia.

Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077)

J. Beck, D. Niederwieser, S. Schwind, 2017, Journal of Cancer Research and Clinical Oncology.

Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial

A. Hinke, H. Schmoll, A. Tannapfel, 2016 .

Detection of Imatinib-Resistant BCR-ABL Mutants in Drug-Naïve Patients: Correlation with Disease Phase and Clonal Evolution but Not with Response to Treatment.

S. McWeeney, B. Druker, M. Deininger, 2004 .

Patients Receiving IL-2 Activated Donor NK Cells Show Lower Incidence of Severe GvHD after Haploidentical SCT.

E. Thiel, C. Loddenkemper, D. Niederwieser, 2007 .

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.

Martin C. Müller, M. Baccarani, G. Rosti, 2011, Blood.

Design and Methods Patients

C. Harrington, P. Paschka, K. Krohn, 2005 .

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.

S. McWeeney, B. Druker, M. Deininger, 2005, Blood.

Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.

D. Niederwieser, H. Al-Ali, R. Krahl, 2004, Haematologica.

Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO – #077

J. Beck, D. Niederwieser, T. Lange, 2013, British journal of haematology.

C. Meisner, L. Kanz, H. Dittmann, 2007, Blood.

In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.

P. Paschka, K. Krohn, B. Druker, 2005, Haematologica.